We anticipate a rebound for embecta

Article Excerpt

The shares of embecta are now down over 60% since Becton Dickinson (see page 17) spun it off as a separate firm in April 2022. That decline is largely due to fears that new GLP-1 weight loss drugs, such as Ozempic, will cut demand from diabetics (many of whom are overweight) for embecta’s insulin products. The company is now re-focusing its businesses, including discontinuing an insulin patch product that would have limited commercial viability. It has also launched a new cost-cutting plan. This new approach should improve embecta’s profitability. It could also enhance its appeal as a potential takeover target. EMBECTA CORP. $15 remains a spinoff buy. The company (Nasdaq symbol EMBC; Manufacturing & Industry sector; Shares outstanding: 58.1 million; Market cap: $871.5 million; Dividend yield: 4.0%; Takeover Target Rating: Medium; www.embecta.com) makes insulin syringes, insulin pens and related products for the treatment of diabetes. Roughly 30 million people in over 100 countries use the company’s products daily. The U.S. accounts for about 55% of its revenue. embecta has…